Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BT-001 and Pembrolizumab in Localised pMMR Rectal Cancer
NCT07687875Phase 1Recruiting
- Start
- Oct 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of udifitimod in rectal cancer. Primary endpoints: Overall incidence of adverse events, Overall incidence of serious adverse events and 1 more. Started Oct 2026; status: recruiting.
02
Drugs
udifitimod
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07687875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07687875.